Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
A. Inoue, Akihiko Gemma(Nippon Medical School), Hiroshi Isobe, Satoshi Oizumi(Hokkaido University), H. Yoshizawa, Yasuo Saijo(Ho Chi Minh City International University), Kenichi Kobayashi(Shiga University of Medical Science), Shunichi Sugawara(Sendai Kousei Hospital), K. Hagiwara, T. Nukiwa(Tohoku University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), S. Morita(Tohoku University)
Cited by 37
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695